ECO2 Plastics Inc. uses a patented process in PET plastic recycling. The company’s patented process, for which ECO2 Plastics is the exclusive worldwide licensee, was developed through a research partnership with Honeywell FM&T and the US Department of Energy.

The company’s approach sets it apart from competitors that deploy water-based recycling processes. Unlike other recyclers, EOC2’s process eliminates the use of water and preserves the environment while delivering a high-quality recycled plastic flake, which is approved by the FDA (Food and Drug Administration) for use in food contact applications.

ECO2 Plastics is the only recycling company that can claim that its plastic recycling technology has little impact on the environment, and is clearly distinguishable from its competitors when it comes to water waste and chemical contamination. So perhaps it came as little surprise that the company announced today that its waterless cleaning process was recognized by Popular Science magazine as one of

...

Wright Medical Group, Inc. (WMGI) recently received the Food and Drug administration (FDA) approval to market its CONSERVE Plus Total Hip Resurfacing System in the U.S. The new system, which has received FDA approval, provides surgeons with a bone-conserving alternative to traditional total hip replacement.   With the FDA approval, Wright Medical can now market CONSERVE Plus in the original femoral and acetabular component configuration in the U.S. as specified in its PreMarket Approval (PMA) application with the FDA. The company also intends to develop additional enhancements to the system. Wright Medical is already marketing its CONSERVE Plus system, which has received FDA approval, with additional features in the international markets.   The CONSERVE Plus system, which has received FDA approval, offers pain relief and restoration of normal hip functions while retaining  maximum of the healthy bone. It preserves future surgery options, including a primary total hip replacement. It ...

Geron Corporation (NASDAQ:GERN) today announced that they have reached an agreements with the Food and Drug Administration to re-initiate clinical trials for spinal cord injury. The company said that they plan to advance clinical development of their human embryonic stem cell (hESC)-based product, GRNOPC1 which will be used for the treatment of spinal cord injuries. The plan is to let Geron Corporation restart the Phase 1 clinical trial of GRNOPC1 in patients who are suffering from complete thoracic spinal cord injury and to support the future expansion of the clinical trial with patients who are suffering from cervical injuries.

Geron Corporation is one of the developers for the first-in-class biopharmaceuticals that is used for the treatment of cancer and chronic degenerative diseases like spinal cord injury, diabetes and heart failure. GRNOPC1 that is being developed by Geron Corporation is made for the treatment of spinal cord injury but Geron is

...

CytRx Corporation (NASDAQ:CYTR) has announced that a paper published in Gerontology journal concluded that molecular chaperone amplification may represent a significant strategy in the designing of anti-aging pharmaceuticals in the near future. CytRx Corporation is a biopharmaceutical research and development company engaged in the development of high-value human therapeutics. The Company’s drug development pipeline includes programs in clinical development for cancer indications, including tamibarotene in a study for the treatment of acute promyelocytic leukemia (APL). CytRx is also developing two drug candidates based on its industry-leading molecular chaperone technology, which aims to repair or degrade misfolded proteins associated with disease.

CytRx believes that the inhibition of molecular chaperones that normally help protect cancer cells from toxic misfolded proteins may result in the selective destruction of cancer cells. CytRx

...

CytRx Corporation (NASDAQ:CYTR) has announced that a paper published in Gerontology journal concluded that molecular chaperone amplification may represent a significant strategy in the designing of anti-aging pharmaceuticals in the near future. CytRx Corporation is a biopharmaceutical research and development company engaged in the development of high-value human therapeutics. The Company’s drug development pipeline includes programs in clinical development for cancer indications, including tamibarotene in a study for the treatment of acute promyelocytic leukemia (APL). CytRx is also developing two drug candidates based on its industry-leading molecular chaperone technology, which aims to repair or degrade misfolded proteins associated with disease.

CytRx believes that the inhibition of molecular chaperones that normally help protect cancer cells from toxic misfolded proteins may result in the selective destruction of cancer cells. CytRx Corporation currently has two clinical-stage molecular chaperone drug candidates and has discovered a series of additional compounds that may provide a pipeline

...

Caraco Pharmaceutical Laboratories, Ltd. reported revenues of $78.4 million in the second fiscal quarter of 2010 ended September, 30, 2009, down from $122.8 million in the same quarter last year.

Caraco Pharmaceutical Laboratories, Ltd had net income of $6.6 million, or $0.17 per diluted share, in the second quarter. The company earned $8.4 million, or $0.21 per diluted share, in the same quarter last year.

Caraco Pharmaceutical Laboratories, Ltd. said that sales of distributed products were down due to lower shipments of its Paragraph IV products and “price erosion” on those products. Distributed products refer to products that the company markets for other companies.

Sales of products made by Caraco Pharmaceutical Laboratories, Ltd. were also down due to a voluntary recall by the company, and actions taken by the Food and Drug Administration (FDA) that resulted in an interruption of manufacturing.

In June 2009, the FDA closed three manufacturing

...

On Monday morning, the Food and Drug Administration panel approved Arzerra, a leukemia treatment that will be marketed and commercialized by GlaxoSmithKline Plc (ADR) (NYSE:GSK). As per the announcement made by the GSK executives, Arzerra is for those patients who have failed to respond to other therapies that cure leukemia. This new drug marketed by GSK was originally developed by GlaxoSmithKline and Genmab A/S, a Danish company. The drug is designed to treat patients with chronic lymphocytic leukemia also known as CLL and for those whose disease has progressed despite previous treatments with other cancer drugs.

GSK is a global healthcare company that is more into the creation and development, manufacturing and marketing of various pharmaceutical products including vaccines and over the counter medicines and other health related

...

Sanofi-Aventis SA (ADR) (NYSE:SNY), France’s biggest pharmaceutical group has accused Hospira Inc and Canada’s Apotex Inc of infringing patents for the cancer drug Taxotere. Sanofi-Aventis has said that both the companies have tried to copy their products. Earlier Sanofi-Aventis have filed separate complaints against Hospira Inc and Apotex Inc that they have violated the patent laws and have attempted to duplicate their top ranging product that is developed and marketed for the treatment of cancer patients. Though the market reacted sharply after the news broke into the market, but there was not much of fluctuation in the shares of Sanofi-Aventis at the end of the day.

Sanofi-Aventis is one of the leading pharmaceutical companies in France and globally as well. The company is into the research, development, manufacturing

...

Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

DrStockPick.com Watch List!

My Picks for Tuesday October 27, 2009, are:

**************************************************************

GSK, GlaxoSmithKline plc

GSK, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, over the counter medicines, and health related consumer products. GSK operates in two segments, Pharmaceutical and Consumer Healthcare.

** The Food and Drug Administration Monday approved Arzerra, a leukemia treatment that will be marketed by GSK for patients who have failed to respond to other therapies.

More about GSK at www.gsk.com

**************************************************************

EVRN, Everock Inc., EVRN.PK

EVRN produces a line of all-natural gourmet vegetable dips and sandwich spreads marketed under the Nature’s Peak brand.

Both

...

Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

Monday October 19, 2009

DrStockPick.com Stock Report!

AMGN, PWRM, JNJ, CSRH, GE, CVAT, TEVA, AQNM

**************************************************************

AMGN, Amgen Inc.

AMGN, a biotechnology company, engages in the discovery, development, manufacture, and marketing of human therapeutics based on advances in cellular and molecular biology.

The Food and Drug Administration wants more information about AMGN’s osteoporosis treatment Prolia before granting marketing approval. It delays a drug seen as a potential blockbuster for the company.

**************************************************************

PWRM, Power 3 Medical Products Inc, PWRM.OB

Power3 Medical Products, Inc. is a leading bio-medical company engaged in the commercialization of neurodegenerative disease and cancer biomarkers, pathways, and mechanisms of diseases through the development of

...